{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:36:32Z","timestamp":1787668592752,"version":"build-2736575974"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The integration of chimeric antigen receptor (CAR) therapies with precision medicine holds potential to impact the treatment landscape for acute myeloid leukemia (AML). Genetic mutations play a role in the efficacy of CAR-T and CAR-NK cells, influencing their crucial role in determining the effectiveness of these cells, as well as their proliferation, persistence, resistance, and safety. This review examines how mutations in FLT3, DNMT3A, NPM1, TP53, TET2, gene fusions involving RUNX1 and KMT2A and other key genes modulate CAR-based immunotherapies, highlighting both vulnerabilities and resistance mechanisms. Recent findings demonstrate that mutations in genes such as DNMT3A and NPM1 enhance antigen expression, thereby improving CAR targeting. In contrast, mutations in TP53 drive immune escape and resistance to therapy. Understanding these mutation-specific effects is essential for tailoring CAR therapies to individual patients, optimizing efficacy while minimizing toxicity. By leveraging genomic profiling and personalized engineering approaches, CAR therapies can be refined to overcome resistance and enhance precision in AML treatment. Future research should focus on integrating multiomic data to develop mutation-adapted CAR strategies, ensuring that patients receive the most effective and personalized immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1653350","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:47:48Z","timestamp":1762429668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Precision medicine with car cells in acute myeloid leukemia: where are we?"],"prefix":"10.3389","volume":"16","author":[{"given":"Larissa C.","family":"Zanetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Tomaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Ferreira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo V.","family":"Campregher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila N.","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126045","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B4","article-title":"In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel vs. standard of care in second-line therapy for relapsed or refractory large B-cell lymphoma (TRANSFORM): interim results","volume":"399","author":"Bishop","year":"2022","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"33","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary Malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary Malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2405538","article-title":"T-cell cancer after CAR T-cell therapy","volume":"390","author":"Mitchell","year":"2024","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2460043","article-title":"T-cell neoplasias and secondary Malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies","volume":"66","author":"Maurer","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e20230903","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at memorial sloan kettering cancer center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Canelo-Vilaseca","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17030","article-title":"Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients","volume":"62","author":"Harrer","year":"2022","journal-title":"Transfusion"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1192907","article-title":"Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830050209","article-title":"Natural\" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910160204","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors","volume":"16","author":"Herberman","year":"1975","journal-title":"I Distribution reactivity specificity Int J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \"Off-the-shelf\" Allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1358668","article-title":"The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation","volume":"15","author":"Hadjis","year":"2024","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","article-title":"Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.1.275.275","article-title":"Subpopulation heterogeneity in human acute myeloid leukemia determined by monoclonal antibodies","volume":"64","author":"Pessano","year":"1984","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114260","article-title":"Immunotherapeutic targeting of surfaceome heterogeneity in AML","volume":"43","author":"Bordeleau","year":"2024","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132359","article-title":"The immunotherapy of acute myeloid leukemia: A clinical point of view","volume":"16","author":"Mosna","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1646.1646","article-title":"Tumor specific glycosylated CD43 is a novel and highly specific target for acute myeloid leukemia and myelodysplastic syndrome","volume":"28","author":"Gillissen","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(84)90001-8","article-title":"A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells","volume":"8","author":"Griffin","year":"1984","journal-title":"Leuk Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000058769","article-title":"CD38 in hematopoietic Malignancies","volume":"75","author":"Konopleva","year":"2000","journal-title":"Chem Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16060","article-title":"Targeting CD157 in AML using a novel, Fc-engineered antibody construct","volume":"8","author":"KKrupka","year":"2017","journal-title":"Oncotarget"},{"key":"B56","article-title":"Detailed analysis of FLT3 expression levels in acute myeloid leukemia","volume":"90","author":"Kuchenbauer","year":"2005","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3401","article-title":"A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia","volume":"91","author":"Legras","year":"1998","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and AML expressing Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19990115)85:2<348::aid-cncr12>3.0.co;2-4","article-title":"Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia","volume":"85","author":"Ross","year":"1999","journal-title":"Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151555","article-title":"CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2\/p27kip1 signaling","volume":"102","author":"Zhang","year":"2017","journal-title":"Haematologica"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1308709","article-title":"The dark side of stemness - the role of hematopoietic stem cells in development of blood Malignancies","volume":"14","author":"Filipek-Gorza\u0142a","year":"2024","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.76050","article-title":"Role of genetic analysis in new treatments of acute myeloid leukemia","author":"Payandeh","year":"2018","journal-title":"Myeloid Leukemia"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-64263-5_12","article-title":"The etiology of acute leukemia","volume":"1","author":"Nichol","year":"2018","journal-title":"Neoplastic Dis Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cells13161392","article-title":"Common driver mutations in AML: biological impact, clinical considerations, and treatment strategies","volume":"13","author":"Nong","year":"2024","journal-title":"Cells"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B69","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.210","article-title":"Molecular therapy for acute myeloid leukaemia","volume":"13","author":"Coombs","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int J Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e318261a342","article-title":"CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations","volume":"21","author":"Rollins-Raval","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: A first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ Acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111238","article-title":"Natural flt3Lg-based chimeric antigen receptor (Flt3-CAR) T cells successfully target flt3 on AML cell lines","volume":"9","author":"Maiorova","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e2122379119","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030496","article-title":"CD123 is consistently expressed on NPM1-mutated AML cells","volume":"13","author":"Perriello","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158452","article-title":"The race is on: biTE vs CART as FLT3-directed immunotherapies in AML","volume":"140","author":"Rohrbacher","year":"2022","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007405","article-title":"Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia","volume":"7","author":"Mansour","year":"2023","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18971","article-title":"FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia","volume":"202","author":"Peschke","year":"2023","journal-title":"Br J Haematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Int J Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT143","article-title":"Abstract CT143: First-in-human, multicenter study of SENTI-202, a CD33\/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic Malignancies including AML: Correlative data","volume":"85","author":"Muftuoglu","year":"2025","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-025-00097-1","article-title":"CD44v6 CAR-T cells target DNMT3A-mutant AML: synergistic enhancement by decitabine","author":"Li","year":"2025","journal-title":"Curr Med Sci"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e1043","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145441","article-title":"Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13148-024-01771-2","article-title":"TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights","volume":"16","author":"Gao","year":"2024","journal-title":"Clin Epigenetics"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-025-00609-8","article-title":"TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model","volume":"14","author":"Kim","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1182\/blood-2024-208025","article-title":"Loss of TET2 creates a distinct immunopeptidome in acute myeloid leukemia","volume":"144","author":"Gu","year":"2024","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat Commun"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"B103","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.11.25325281","article-title":"Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53","author":"Li","year":"2025","journal-title":"medRxiv"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1428653","article-title":"Master regulator: p53's pivotal role in steering NK-cell tumor patrol","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e70715","DOI":"10.1111\/jcmm.70715","article-title":"CAR19\/22\u2009T-cell cocktail therapy combined with autologous stem cell transplantation for a patient with mosaic TP53 mutation and 17p deletion","volume":"29","author":"Shen","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241306236","article-title":"Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed\/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report","volume":"13","author":"Cai","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1497736","article-title":"Case report: A novel third-generation anti-CD19\/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma","volume":"15","author":"Luo","year":"2024","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010087","article-title":"Fatal progression of mutated TP53-associated clonal hematopoiesis following anti-CD19 CAR-T cell therapy","volume":"30","author":"Eder","year":"2023","journal-title":"Curr Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00024-2","article-title":"Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells","volume":"16","author":"Mueller","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102713","article-title":"The black hole: CAR T cell therapy in AML","volume":"15","author":"Atilla","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01230-z","article-title":"Decitabine may improve CAR-T efficacy in refractory\/relapsed acute leukemia patients carrying TP53 alterations","volume":"56","author":"Qu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02235-x","article-title":"Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens","volume":"43","author":"Walsh","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","article-title":"CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial","volume":"18","author":"Yin","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1002\/hem3.70006","article-title":"Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia","volume":"8","author":"Zhang","year":"2024","journal-title":"Hemasphere"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01011-5","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Awad","year":"2021","journal-title":"Leukemia"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2024.00176","article-title":"Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer","volume":"4","author":"Mirgayazova","year":"2024","journal-title":"Explor Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1182\/blood-2023-180180","article-title":"DNMT3A-mutated stem and progenitor cells contribute to altered T cell activation in clonal hematopoiesis","volume":"142","author":"Safina","year":"2023","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e2024029","DOI":"10.4084\/MJHID.2024.029","article-title":"FLT3 mutated acute myeloid leukemia after CD19 CAR-t cells","volume":"16","author":"Galli","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-807438","article-title":"The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia","volume":"131","author":"Straube","year":"2018","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238899","article-title":"CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice","volume":"116","author":"Martelli","year":"2010","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166107","article-title":"CAR.CD123-NK cells have an equally effective but safer off-tumor\/on-target profile as compared to CARCD123-T cells for the treatment of AML","volume":"140","author":"Caruso","year":"2022","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120944","article-title":"Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors","volume":"209","author":"Ni","year":"2012","journal-title":"J Exp Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029538","article-title":"Is there natural killer cell memory and can it be harnessed by vaccination? NK cell memory and immunization strategies against infectious diseases and cancer","volume":"10","author":"Sun","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617589","article-title":"Anti-CD19 CAR-T cell therapy in relapsed\/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e70326","DOI":"10.1002\/cam4.70326","article-title":"Recent developments and evolving therapeutic strategies in KMT2A-rearranged acute leukemia","volume":"13","author":"Yin","year":"2024","journal-title":"Cancer Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e157101","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1653350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:47:49Z","timestamp":1762429669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1653350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":131,"alternative-id":["10.3389\/fimmu.2025.1653350"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1653350","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1653350"}}